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The possibility of health benefits associated with dietary
omega-3 polyunsaturated fatty acids (𝜔-3 PUFAs) has been
described for several chronic conditions, including cardio-
vascular, neurodegenerative, and neoplastic diseases. A large
body of evidence has emerged over the past years to show
the critical role played by inflammation in the pathogenesis
of these diseases, previously not considered inflammation
related. Therefore, it has been recently hypothesized that 𝜔-
3 PUFAs’ effects may be related, at least in part, to their
direct anti-inflammatory activity as well as to that of their
oxygenated metabolites (17-HDHA, 18-HEPE, resolvins, and
protectins). In this special issueG. Calviello and collaborators
summarize and comprehensively discuss the current knowl-
edge regarding the modulating effects of 𝜔-3 PUFAs on the
production of inflammatory cytokines and proresolving or
protective lipid mediators in the context of inflammatory,
metabolic, neurodegenerative, and neoplastic diseases.
S. M. Lee and W. S. An present a review on the beneficial
effects of 𝜔-3 PUFAs on cardiovascular diseases and possi-
ble cardioprotective mechanisms of 𝜔-3 PUFAs in chronic
kidney disease (CKD) patients. They highlight their ability
to reduce inflammation, decrease oxidative stress, inhibit
platelet activity, exert antiarrhythmic effects, and improve
triglyceride levels, both in the general population and inCKD
patients.
Moreover, a research article by B. Parada et al. is pre-
sented showing that 𝜔-3 PUFAs inhibit the development of
premalignant andmalignant lesions in a rat model of bladder
cancer, possibly not only through their anti-inflammatory
properties, but also by their ability to inhibit oxidative stress,
proliferation, and angiogenesis.
It is known that local inflammation plays a central
role in the development of colon cancer, and it has been
suggested that its suppression may prevent the development
of this malignancy. However, the role of nonsteroidal anti-
inflammatory drugs (NSAID) in colitis is controversial, and
aggravation of disease due to these compounds has been
described. T. Ko¨hnke et al. in their paper use the murine
dextran-sodium-sulfate- (DSS-) induced colitis model and
demonstrate that the treatment of animals with acetylsalicylic
acid (ASA) decreases colitis activity and increases the for-
mation of 𝜔-3 PUFA-derived lipid mediators with high anti-
inflammatory potential, such as 17-hydroxy docosahexaenoic
acid (17-HDHA), a docosahexaenoic (DHA, 22:6 𝜔-3) oxy-
genated metabolite. This finding suggests that the metabolic
transformation of DHA incorporated in colon cells in the
presence of ASA could, at least in part, explain the colon
cancer preventive activity of this drug, and it might argue for
a synergistic effect of ASA and 𝜔-3 PUFA in the prevention
of colon cancer.
The hypothesis that dietary treatment with 𝜔-3 PUFAs
may potentiate the effect of antineoplastic drugs has been
comprehensively examined by N. Merendino et al. Their
review is focused on the current knowledge supporting the
potential use of DHA as an adjuvant in tumor chemotherapy,
since it has been reported that this fatty acid may enhance
the uptake of anticancer drugs, regulate the oxidative status
of tumor cells, and inhibit tumor cell invasion andmetastasis.
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Another research article is presented by S. Shin et al.,
showing that DHA induces simultaneously apoptosis and
autophagy in prostate cancer cells expressing mutant p53.
The authors find that DHA exerts such antineoplastic effects
by inducing the generation of mitochondrial reactive oxygen
species (ROS) and the ROS-mediated Akt-mTOR signaling.
Several other biological and molecular mechanisms have
been so far described to explain the anticancer effects of 𝜔-3
PUFAs in prostate cancer. A detailed overview of the possible
mechanisms so far hypothesized is presented by Z. Gu and
colleagues.The authors report that a large body of preclinical
experimental work has demonstrated the high sensitivity of
prostate cancer to the protective action of 𝜔-3 PUFAs, while
in contrast it has not been definitely established whether
the ingestion of increased levels of these fatty acids may
actually have a protective effect in prostate cancer patients.
This represents a highly controversial issue, as outcomes of
the epidemiological studies in patients bearing this and other
kinds of cancer appear to be conflicting. Several reasons can
explain these divergences, and these are discussed here by Z.
Gu et al.
One possible reason for discrepancies in 𝜔-3 PUFA stud-
ies, observed also among the interventional trials performed
in cardiovascular patients, is highlighted by B. B. Albert
et al. in this special issue. This paper discusses the possibility
that the easy oxidation of the supplemented 𝜔-3 PUFAs
to lipid peroxides and other secondary oxidation products
may make them ineffective or even harmful. The authors
therefore recommend that all clinical trials investigating 𝜔-
3 PUFA harms or benefits report the results of simple assays
determining the oxidative state of an oil. This recommen-
dation appears appropriate also in view of the numerous
observations [1] suggesting that very high doses of𝜔-3 PUFAs
ingested by “high consumers” of fish and leading to very high
incorporation of these fatty acids in plasma lipids, may result
in high and harmful tissue levels of oxidized 𝜔-3 PUFAs.This
may result in a lack of health benefits or even in the induction
of carcinogenic effects, such as those observed recently in
some epidemiological studies.
This special issue, besides underlining the importance of
identifying and ingesting an appropriate amount of nonoxi-
dized 𝜔-3 PUFAs, also drives attention to the importance of
an optimal dietary balance between 𝜔-3 and 𝜔-6 PUFAs, that
leads to an appropriate 𝜔-6/𝜔-3 PUFA ratio in our tissues.
The review by E. Murru et al. discusses the results that have
so far demonstrated the relationship existing between the 𝜔-
6/𝜔-3 PUFA ratio present in tissues and the dietary form
of these fatty acids. They focus on the findings that have so
far shown a more efficient incorporation of eicosapentaenoic
acid (EPA) and DHA into tissue phospholipids (PL), when
they are mainly esterified to PL already in the diet.
Finally, the importance of establishing an appropriate
dose of dietary 𝜔-3 PUFAs, depending on the form of fatty
acid supplementation and on the age and conditions of the
subjects, is emphasized in the research article by J. Luo et al.
They find that the same fish-oil-enriched diet given to dams
breeding piglets or to weaning piglet causes a positive effect
only on the growth of piglets breast-fed by the fish-oil-
supplemented dams.That effect has been related to a reduced
tissue production of proinflammatory cytokines. On the
contrary, the piglets directly supplemented with fish oil show
reduced growth and higher tissue levels of inflammatory
cytokines.
On the whole, the papers contained in this special issue
aim to examine the beneficial effects of 𝜔-3 PUFAs in several
chronic diseases and physiological conditions as well as to
identify and examine the molecular mechanisms underlying
these effects. Moreover, they highlight the importance of
establishing and using in the studies a proper 𝜔-3 PUFA
supplementation, in terms of amount (daily dose), maximal
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